Immunological and prognostic significance of novel ferroptosis-related genes in soft tissue sarcoma

Jiazheng Zhao¹, Yi Zhao¹, Xiaowei Ma¹, Helin Feng¹, Rongmin Cui²*

¹ Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China, ² Department of Operating Room, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China

* rongmincui0311@163.com

Abstract

Background
Ferroptosis has exhibited great potential in the treatment of cancer and has gained widespread attention in soft tissue sarcoma (STS). The aim was to explore the immunological and prognostic significance of novel ferroptosis-related genes in STS.

Methods
We identified ferroptosis-related differentially expressed genes (DEGs) in STS to construct the networks of enrichment analysis and protein-protein interaction. Subsequently, hub genes with prognostic significance were localized and a series of prognostic and immune analyses were performed.

Results
40 ferroptosis-related DEGs were identified, of which HELLS, STMN1 EPAS1, CXCL2, NQO1, and IL6 were classified as hub genes and were associated with the prognosis in STS patients. In the results of the immune analysis, PDCD1, CTLA4, TIGIT, IDO1 and CD27 exhibited consistent intense correlations as immune checkpoint genes, as well as macrophage, neutrophil, cytotoxic cell, dendritic cell, interdigitating dendritic cell and plasmacytoid dendritic cell as immune cells. EPAS1 and HELLS might be independent prognostic factors for STS patients, and separate prognostic models were constructed by using them.

Conclusions
We recognized novel ferroptosis-related genes with prognostic value in STS. Furthermore, we searched out potential immune checkpoints and critical immune cells.
Introduction

Soft tissue sarcoma (STS) is a group of malignant tumors originating from mesenchymal tissue and containing multiple histological subtypes [1]. The prognosis of partial STS is poor with no effective treatment and the precise prediction of the prognosis for STS patients is a challenging topic [2]. The previous view was that immunotherapy was unpromising in STS, but this has been reversed in recent years [3].

Ferroptosis is an emerging phenotype of regulated cell death (RCD) which relies on reactive oxygen species deposition mediated by iron catalysis and lipid peroxidation [4]. Ferroptosis performs an essential role in the initiation, progression and prognosis of multiple diseases [5]. Meanwhile, ferroptosis has exhibited great potential in the treatment of cancer and has gained widespread attention in STS as well [6]. Recent studies have revealed that ferroptosis and tumor immunity can be mutually regulated [7, 8].

In the present study, differentially expressed genes (DEGs) were identified through the Gene Expression Omnibus (GEO) database, the FerrDb database, the Immunology Database and Analysis Portal (ImmPort) database, and the networks of enrichment analysis and protein-protein interaction (PPI) were constructed. Prognostic and immune analyses were performed through the Cancer Genome Atlas (TCGA) database. The aim was to explore the immunological and prognostic significance of novel ferroptosis-related genes in STS.

Materials and methods

Data sources

We downloaded RNA-seq data from the GEO database (https://www.ncbi.nlm.nih.gov/geo/) in the GSE21122, GSE6481 and GSE2719 datasets, and all three datasets were from the GPL96 platform. Selected samples from GSE21122 included leiomyosarcoma (26), dedifferentiated liposarcoma (46), myxoid liposarcoma (20), pleomorphic liposarcoma (23), myxofibrosarcoma (31), pleomorphic fibrosarcoma (3), normal human fat (9); selected samples from GSE6481 included synovial sarcoma (16), malignant peripheral nerve sheath tumor (3); selected samples from GSE2719 included gastrointestinal stromal tumor (2), round cell tumor (4). In total, from the GSE21122, GSE6481 and GSE2719 datasets, we selected 174 STS samples covering 10 subtypes as the experimental group and 9 normal human fat samples as the control group for difference analysis. Furthermore, we chose the GSE63157 dataset for external validation of the gene prognostic value. We downloaded RNA-seq and clinical data from the TCGA database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) for 263 samples, including leiomyosarcoma (105), dedifferentiated liposarcoma (59), undifferentiated pleomorphic sarcoma (51), myxofibrosarcoma (25), synovial sarcoma (10), malignant peripheral nerve sheath tumor (9), desmoid tumor (2), unclassified sarcoma (2). RNA-seq data in FPKM format was converted to TPM format and log2 transformed. We downloaded the lists of 259 ferroptosis-related genes and 2498 immune-related genes from the FerrDb database (http://www.zhounan.org/ferrd) [9] and ImmPort database (https://immport.niaid.nih.gov) [10], respectively. All material was sourced from public databases and did not involve informed consent from participants.

Data pre-processing and differential analysis

We downloaded the GSE2719, GSE6481, and GSE21122 datasets by the GEOquery package of R [11]. Probes with one probe corresponding to more than one molecule were removed, when probes corresponding to the same molecule were encountered, and only the probe with the highest signal value was retained. For the filtered data, we used the ComBat function of the sva
package to remove inter-batch differences, box plots to present the normalization result, prin-
cipal component analysis (PCA) and uniform manifold approximation and projection
(UMAP) plots to present the clustering result (S1A–S1F Fig). Differential analysis was carried
out by the limma package [12] and visualized using the ggplot2 package and ComplexHeatmap
package [13]. The adjusted p value (false discovery rate, FDR) < 0.05 and | log fold change
(FC)| > 1 for the DEGs were set as screening conditions.

Functional enrichment analysis and PPI networks construction
Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes
(KEGG) enrichment analysis and Gene Set Enrichment Analysis (GSEA) were implemented
through the clusterProfiler package of R [14]. FDR < 0.05 for the enriched item was consid-
ered statistically significant. After predicting the interactions between DEGs in the Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (https://string-db.org/)
[15] by setting the combined score > 0.4, the PPI networks were built using Cytoscape [16]
and cytoHubba [17] respectively.

Hub genes identification and prognostic models construction
Through the TCGA database, high expression and low expression groups were divided by
the median of DEGs expression and survival analysis was performed with the survival
package of R [18]. DEGs with potential prognostic significance were identified as hub
genes by log-rank analysis and visualization was achieved through the survminer package.
The Wilcoxon rank sum test was chosen for correlation analysis of hub genes expression
with clinical variables, and the ggplot2 package was used for visualization. All clinical vari-
ables of STS were integrated into univariate Cox regression, parameters were included in
overall survival (OS) and progression free survival (PFS), and variables that were signifi-
cant for univariate analysis were integrated into multivariate Cox regression. After evalu-
ating significant variables in the multivariate analysis by the timeROC package, they were
incorporated into a nomogram to construct the model [19]. The population of the model
was 263 patients with well-defined STS, from the TCGA database and screened with corre-
sponding clinical information, and the model was validated by a calibration curve, with
visualization implemented through the rms package. The results were considered statisti-
cally significant at p < 0.05.

Immune analysis
Through the TCGA database, high expression and low expression groups were classified
according to the upper and lower quartiles of DEGs expression and the GSVA package of R
accompanied by Spearman correlation test was applied for immune analysis [20]. 7 popular
immune checkpoint genes (ICGs) [21, 22] and 24 immune cells composing the main tumor
immune microenvironment [23] were included by applying the CIBERSORT deconvolution
algorithm, and the ggplot2 package was used to construct co-expression plots. The results were
considered statistically significant at p < 0.05.

Statistical analysis
Statistical analysis relied on R software (version 3.6.3) and Cytoscape software (version 3.8.2).
Results

Ferroptosis-related DEGs identification in STS

A total of 927 DEGs for STS were identified in 183 samples from the GSE21122, GSE6481 and GSE2719 datasets, including 345 for up-regulation and 582 for down-regulation. The volcano plot covered all genes in differential analysis (Fig 1A) and the heatmap displayed the top 20 DEGs for each of up-regulation and down-regulation (Fig 1B). Among them, a total of 40 genes were associated with ferroptosis (Table 1), including 6 for up-regulation and 34 for down-regulation (Fig 1C).

Ferroptosis-related DEGs enrichment analysis

After conducting enrichment analysis on the 40 ferroptosis-related DEGs, the top 5 enriched entries and pathways were obtained to construct the GO enrichment network (Fig 2A) and the KEGG enrichment network (Fig 2B) respectively. GO analysis indicated that these genes functioned in response to metalion (GO: 0010038), response to corticosteroid (GO: 0031960), response to nutrient levels (GO: 0031667), response to oxidative stress (GO: 0006979) and reactive oxygen species metabolic process (GO: 0072593). KEGG analysis suggested that

Fig 1. Identification of ferroptosis-related DEGs in STS. (A) The volcano plot of all genes. (B) The heatmap of the top 20 DEGs for each of up-regulation and down-regulation. (C) The Venn diagram of the intersection among up-regulated DEGs, down-regulated DEGs and ferroptosis-related genes.

https://doi.org/10.1371/journal.pone.0262234.g001
corresponding genes were significantly associated with glutathione metabolism (hsa00480), FoxO signaling pathway (hsa04068), HIF-1 signaling pathway (hsa04066), legionellosis (hsa05134) and Kaposi sarcoma-associated herpesvirus infection (hsa05167).

Table 1. Ferroptosis-related DEGs in STS.

| No. | Genes      | Expression | FDR   | log FC |
|-----|------------|------------|-------|--------|
| 1   | CDKN2A     | Up-regulation | <0.001 | 2.012  |
| 2   | HELLS      | Up-regulation | <0.001 | 2.015  |
| 3   | GDF15      | Up-regulation | 0.020 | 1.447  |
| 4   | STIM1      | Up-regulation | <0.001 | 1.162  |
| 5   | RRM2       | Up-regulation | <0.001 | 2.550  |
| 6   | AURKA      | Up-regulation | <0.001 | 1.447  |
| 7   | PGD        | Down-regulation | 0.001 | -1.294 |
| 8   | ACO1       | Down-regulation | <0.001 | -1.714 |
| 9   | GABARAPL1  | Down-regulation | <0.001 | -1.521 |
| 10  | EGFR       | Down-regulation | 0.002 | -1.189 |
| 11  | CDO1       | Down-regulation | <0.001 | -2.184 |
| 12  | EPAS1      | Down-regulation | <0.001 | -1.969 |
| 13  | HILPDA     | Down-regulation | 0.007 | -1.002 |
| 14  | LPIN1      | Down-regulation | <0.001 | -1.003 |
| 15  | TLR4       | Down-regulation | <0.001 | -1.037 |
| 16  | AKR1C1     | Down-regulation | <0.001 | -2.875 |
| 17  | AKR1C3     | Down-regulation | <0.001 | -2.294 |
| 18  | GCLC       | Down-regulation | <0.001 | -1.694 |
| 19  | NQO1       | Down-regulation | <0.001 | -2.045 |
| 20  | MT1G       | Down-regulation | <0.001 | -1.565 |
| 21  | SCD        | Down-regulation | <0.001 | -2.246 |
| 22  | CDKN1A     | Down-regulation | <0.001 | -1.196 |
| 23  | PRDX6      | Down-regulation | <0.001 | -1.083 |
| 24  | PLIN2      | Down-regulation | 0.018 | -1.054 |
| 25  | ZFP36      | Down-regulation | <0.001 | -2.141 |
| 26  | CAV1       | Down-regulation | <0.001 | -1.255 |
| 27  | PTGS2      | Down-regulation | <0.001 | -1.866 |
| 28  | DUSP1      | Down-regulation | <0.001 | -1.566 |
| 29  | NCF2       | Down-regulation | 0.002 | -1.049 |
| 30  | BNIP3      | Down-regulation | 0.001 | -1.602 |
| 31  | PCK2       | Down-regulation | <0.001 | -1.341 |
| 32  | TXNIP      | Down-regulation | <0.001 | -1.333 |
| 33  | IL6        | Down-regulation | <0.001 | -2.806 |
| 34  | CXCL2      | Down-regulation | <0.001 | -3.999 |
| 35  | MAP3K5     | Down-regulation | <0.001 | -1.599 |
| 36  | SLC2A3     | Down-regulation | 0.008 | -1.129 |
| 37  | ACSF2      | Down-regulation | <0.001 | -1.181 |
| 38  | TF         | Down-regulation | <0.001 | -3.001 |
| 39  | ATF3       | Down-regulation | <0.001 | -1.931 |
| 40  | GPX4       | Down-regulation | <0.001 | -1.325 |

DEGs, differentially expressed genes; STS, soft tissue sarcoma; FC, fold change.

https://doi.org/10.1371/journal.pone.0262234.t001
Fig 2. Enrichment analysis of ferroptosis-related DEGs in STS. (A) The network of GO enrichment analysis for the top 5 entries. (B) The network of KEGG enrichment analysis for the top 5 pathways.

https://doi.org/10.1371/journal.pone.0262234.g002
PPI networks construction

Interactions of ferroptosis-related DEGs in STS were predicted by STRING and a PPI network covering 38 nodes and 97 edges was structured by Cytoscape (Fig 3A). Subsequently we used cytoHubba to further identify the top 25 genes and build a 25-node, 69-edge PPI network (Fig 3B).

Hub genes identification

Survival analysis revealed the potential prognostic value of HELLS, STMN1 in up-regulation DEGs and EPAS1, CXCL2, NQO1, IL6 in down-regulation DEGs, with high expression of HELLS, STMN1 and low expression of EPAS1, CXCL2, NQO1, IL6 suggesting a short OS in STS patients (Fig 4A). Accordingly, these 6 genes were identified as hub genes for further
study and the association between hub genes and STS clinical variables was analyzed (Fig 4B). Compared to male patients with STS, female patients exhibited high expression of HELLS, STMN1, NQO1 and low expression of EPAS1. Compared to other histological types, leiomyosarcoma showed high expression of HELLS, EPAS1, NQO1 and low expression of IL6. Besides, HELLS and STMN1 was highly expressed in STS metastatic patients compared to non-metastatic patients.

Hub genes GSEA analysis

The 263 STS samples from TCGA database were divided into low expression and high expression groups based on the median of hub gene expression respectively for GSEA analysis. GSEA manifested significant differences in enrichment of MSigDB Collection (FDR < 0.05) and significant-enriched gene sets were ranked based on normalized enrichment score (NES) values. The top-two most significant-enriched gene sets for HELLS were G alpha signaling events and olfactory transduction (Fig 5A). The top-two most significant-enriched gene sets for STMN1 were signaling by Rho GTPases and processing of capped intron-containing premRNA (Fig 5B). The top-two most significant-enriched gene sets for EPAS1 were M-phase and metabolism of amino acids and derivatives (Fig 5C). The top-two most significant-enriched gene sets for CXCL2 were neuronal system and neuroactive ligand receptor interaction (Fig 5D). The top-two most significant-enriched gene sets for NQO1 were signaling by interleukins and Leishmania infection (Fig 5E). The top-two most significant-enriched gene sets for IL6 were signaling by interleukins and GPCR-ligand binding (Fig 5F).

Fig 5. GSEA analysis of hub genes. (A) HELLS. (B) STMN1. (C) EPAS1. (D) CXCL2. (E) NQO1. (F) IL6.

https://doi.org/10.1371/journal.pone.0262234.g005
EPAS1 and HELLS might be independent prognostic factors for STS patients

Clinical variables for STS and the expression of 6 hub genes were included in univariate Cox regression analysis and those factors of significance were further subsumed into multivariate Cox regression analysis. The results revealed that when the prognostic indicator was OS, high grade residual tumor, metastasis, positive margin status, high expression of HELLS and STMN1, low expression of EPAS1, CXCL2, NQO1, IL6 were associated with poor prognosis. Furthermore, residual tumor, metastasis status, margin status, EPAS1 expression might be independent prognostic factors for OS in STS patients (Table 2). When the prognostic indicator was PFS, high grade residual tumor, metastasis, positive margin status, HELLS high expression were associated with poor prognosis. Residual tumor, metastasis status, margin status, HELLS expression might be independent prognostic factors for PFS in STS patients (Table 3).

Validation of EPAS1 and HELLS prognostic value

Predictive efficacy of EPAS1 and HELLS for prognosis was internally verified using time-dependent receiver operating characteristic (ROC) curves in TCGA database (Fig 6A and 6B). Subsequently, predictive efficacy of EPAS1 and HELLS for prognosis was externally validated using time-dependent ROC curves in GEO database, which exhibited similar prognostic value (Fig 6C and 6D).

Construction and evaluation of prognostic models for STS patients

The statistically significant results of the multivariate Cox regression analysis were used to construct the separate nomogram for prediction models of OS (Fig 7A) and PFS (Fig 7B) in STS patients. For both patients with primary STS and metastatic STS, the indicators for each nomogram were derived from the primary tumor foci. The C-indexes for OS and PFS model were 0.756 (0.719–0.794) and 0.782 (0.756–0.808) respectively. Calibration curves for the

| Variables | Total(N) | Univariate analysis | Multivariate analysis |
|-----------|----------|---------------------|----------------------|
|           |          | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
| Age (>60 vs. < = 60) | 263 | 1.285 (0.864–1.911) | 0.216 |  |  |
| Gender (Male vs. Female) | 263 | 0.905 (0.607–1.349) | 0.623 |  |  |
| Race (White vs. Others) | 254 | 0.725 (0.350–1.501) | 0.386 |  |  |
| Histological type (Leiomyosarcoma vs. Others) | 263 | 0.913 (0.611–1.363) | 0.656 |  |  |
| Radiation therapy (Yes vs. No) | 257 | 0.864 (0.557–1.339) | 0.513 |  |  |
| Residual tumor (R2 vs. R0&R1) | 235 | 8.365 (3.972–17.617) | <0.001 | 22.480 (6.480–77.987) | <0.001 |
| Metastasis status (Yes vs. No) | 179 | 2.888 (1.762–4.732) | <0.001 | 3.493 (1.852–6.585) | <0.001 |
| Margin status (Positive vs. Negative) | 213 | 1.957 (1.215–3.151) | 0.006 | 1.879 (1.054–3.350) | 0.032 |
| HELLS (High vs. Low) | 263 | 1.883 (1.250–2.836) | 0.002 | 1.272 (0.603–2.683) | 0.527 |
| STMN1 (High vs. Low) | 263 | 1.859 (1.242–2.783) | 0.003 | 0.844 (0.416–1.712) | 0.638 |
| EPAS1 (Low vs. High) | 263 | 1.627 (1.093–2.424) | 0.017 | 2.698 (1.347–5.406) | 0.005 |
| CXCL2 (Low vs. High) | 263 | 1.625 (1.089–2.425) | 0.017 | 1.142 (0.531–2.455) | 0.735 |
| NQO1 (Low vs. High) | 263 | 1.504 (1.009–2.242) | 0.045 | 1.307 (0.737–2.319) | 0.360 |
| IL6 (Low vs. High) | 263 | 1.624 (1.085–2.432) | 0.018 | 1.191 (0.557–2.544) | 0.652 |

OS, overall survival; STS, soft tissue sarcoma.
models of OS (Fig 7C) and PFS (Fig 7D) confirmed the consistency of the predicted prognosis with the actual outcome.

**Association of hub genes expression and ICGs**

CXCL2 and IL6 were shown to be immunologically relevant in 6 hub genes (Fig 8A). We correlated hub genes with ICGs and presented the results in co-expression heatmaps. CXCL2 and IL6 showed consistent results, with both CXCL2 and IL6 positively linked to the expression of PDCD1, CTLA4, TIGIT, IDO1 and CD27 (Fig 8B and 8C). Consistency of results and significant association with ICGs were not demonstrated in HELLS, STMN1, EPAS1 and NQO1 (Fig 8D–8G).

**Association of hub genes expression and immune cells infiltration**

6 hub genes were subsequently correlated with 24 immune cells in the tumor microenvironment (Fig 9A). In addition to CXCL2 and IL6, we observed that HELLS was also strongly associated with immune cells and exhibited the consistent result with CXCL2 and IL6. CXCL2 and IL6 with down-regulated in STS were significantly positively related to macrophage, neutrophil, cytotoxic cell, dendritic cell (DC), interdigitating dendritic cell (iDC), plasmacytoid dendritic cell (pDC) (all r > 0.3) (Fig 9B and 9C), and HELLS with up-regulated in STS was comparatively negatively correlated with macrophage, neutrophil, cytotoxic cell, DC, iDC, pDC (all r < -0.3) (Fig 9D) Consistency of results and significant association with immune cells were not demonstrated in STMN1, EPAS1 and NQO1.

**Discussion**

STS is a set of heterogeneous malignancies involving over 100 different histological types, with widely varying treatment outcomes [24]. In general, current therapies are only effective in a small proportion of STS, with limited efficacy in most STS and even recurrence in more than 50% of patients [25]. Although it was considered that STS was extremely insensitive to
immune responses in the past, which precluded the application of immunotherapy to STS, recent studies have demonstrated a large degree of immune heterogeneity within the subclass of STS and some positive responses to immunotherapy have also been reported in successive clinical trials [26, 27]. Partial STS subtypes, including dedifferentiated liposarcoma, leiomyosarcoma, embryonal rhabdomyosarcoma and undifferentiated pleomorphic sarcoma, have been identified as featuring high levels of immune cells infiltration and ICGs expression, and exhibit a potentially active reaction to immune checkpoint inhibitors (ICIs) therapy [3]. Consequently it is essential to locate critical ICGs and immune infiltration factors adapted to STS.

Currently, the availability of immunotherapy alone is severely limited in patients with most tumor types. Since extensive crossover between immunotherapy and non-apoptotic RCD...
Fig 7. Visualization of prognostic prediction models in STS. (A) The nomogram for predicting OS. (B) The nomogram for predicting PFS. (C) The calibration curve to evaluate the OS nomogram. (D) The calibration curve to evaluate the PFS nomogram.

https://doi.org/10.1371/journal.pone.0262234.g007
mechanisms has been detected, non-apoptotic cancer cell death accompanied by immunomodulation is considered an exceedingly promising strategy for cancer treatment [28]. Ferroptosis, a neoteric form of RCD with unique biological and morphological features, has been shown to interact with the tumor immune response and can influence immunotherapeutic efficacy on the one hand [8], and in turn is regulated by immune cells on the other [7]. In the present study, based on ferroptosis-related genes in STS, we identified potential ICGs including PDCD1, CTLA4, TIGIT, IDO1 and CD27, which might serve as important targets for immunotherapy. In addition, we explored a group of closely related immune cells including macrophage, neutrophil, cytotoxic cell, DC, iDC and pDC, which might act as pivotal regulators in the immune microenvironment of STS. Interestingly, we observed high concordance of immune analysis results for HELLS with CXCL2 and IL6, revealing for the first time a possible immunological effect of HELLS in tumor.

Among dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma and leiomyosarcoma, it has been confirmed that tumors with high immunogenic gene profiles are accompanied by high levels of PDCD1 expression [29]. PD-1, as the most researched immune checkpoint, is encoded by PDCD1 and also occupies an important position in STS study. More than half of the samples in a STS cohort had positive expression of PD-1 on immune cells [30], and PD-1 expression is also generally considered to be associated with the prognosis of STS patients [31, 32]. Moreover, CTLA4, IDO1 and other ICGs have demonstrated varying degrees of value for STS management [3]. In terms of immune cells, macrophage has been established as a significant player in several sarcoma types [33], with the modification of the macrophage phenotype from tumor-promoting to tumor-suppressing regarded as a promising option for STS treatment [34]. And a range of immunotherapies targeting DC, iDC and pDC may be well tolerated in patients with refractory STS due to their excellent immunological response and safety profile, as well as offering the opportunity to prevent recurrence of sarcoma [35]. On balance, for most STS subtypes, immunotherapy may be required novel regimens and combinations [34].

In addition, we substantiated that EPAS1 and HELLS might act as independent prognostic predictors of STS, leading to the construction of two efficient prognostic models.
patients with primary STS and metastatic STS, the indicators for each nomogram were derived from the primary tumor foci. However, the obtained model still needs to be further verified in an independent cohort. The expression of 6 hub genes was discovered to be associated with survival during the model construction, with EPAS1, STMN1, CXCL2, NQO1 being identified for the first time in STS. EPAS1 is a diver of ferroptosis [36], compared to normal tissue, which is expressed at lower levels in most human STS [37]. Zhu et al. found that up-regulation of EPAS1 significantly enhanced the growth inhibition of gastric adenocarcinoma and that targeting EPAS1 might be an alternative therapeutic approach for cancer [38]. Relatively, HELLS, NQO1 are suppressors of ferroptosis [39, 40]. Law et al. suggested that HELLS mediated epigenetic silencing of various cancer suppressor genes and evidenced in hepatocellular carcinoma that its overexpression potentiated tumor cell migration and proliferation [41]. Huang et al. identified high expression and prognostic impact of HELLS in STS samples [42], which also underpinned our findings. In the TCGA database of STS samples, GSEA indicated that NQO1 was closely connected to interleukin-related signaling pathways. NQO1 has been confirmed to

---

**Fig 9. Analysis of immune cells in STS.** (A) The correlation of 6 hub genes expression with 24 immune cells. (B) The correlation of CXCL2 expression with 6 immune cells. (C) The correlation of IL6 expression with 6 immune cells. (D) The correlation of HELLS expression with 6 immune cells.

https://doi.org/10.1371/journal.pone.0262234.g009
interact with interleukins in a variety of cancers, thereby affecting the inflammatory response and participating in the immune regulation associated with the tumor microenvironment [43, 44]. As for STMN1, CXCL2 and IL6, they are currently treated as biomarkers of ferroptosis and their expression is monitored for down-regulation once ferroptosis occurs [45, 46]. STMN1 is commonly recognized as an oncogene, and its up-regulation is tightly linked to the malignant behaviour and poor prognosis of various tumors [47]. In leiomyosarcoma, STMN1 has also been characterised by high expression and can be a sensitive biomarker with strong diagnostic efficacy [48, 49]. Our study revealed the potential immunological relevance and clinical value of these novel ferroptosis-related genes, which might contribute to the precise treatment and prognostic prediction of patients with STS.

Conclusions

In conclusion, we identified novel ferroptosis-related genes with prognostic value in STS. Furthermore, we searched out potential immune checkpoints and critical immune cells.

Supporting information

S1 Fig. Evaluation of data pre-processing from the GEO database. Comparison of box plots (A-B), PCA plots (C-D) and UMAP plots (E-F) before and after data pre-processing. (TIF)

Author Contributions

Conceptualization: Jiazheng Zhao, Rongmin Cui.

Formal analysis: Jiazheng Zhao, Helin Feng, Rongmin Cui.

Methodology: Jiazheng Zhao, Helin Feng, Rongmin Cui.

Validation: Yi Zhao, Xiaowei Ma.

Visualization: Yi Zhao, Xiaowei Ma.

Writing – original draft: Jiazheng Zhao.

Writing – review & editing: Helin Feng, Rongmin Cui.

References

1. Ferrari A, Dirksen U, Bielack S. Sarcomas of Soft Tissue and Bone. Prog Tumor Res. 2016; 43:128–41. https://doi.org/10.1159/000447083 PMID: 27595362

2. Callegaro D, Miceli R, Mariani L, Raut CP, Gronchi A. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017; 123:2802–20. https://doi.org/10.1002/cncr.30721 PMID: 28493287

3. Zhu M, Shenasa E, Nielsen TO. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. Cancer Treat Rev. 2020; 91:102115. https://doi.org/10.1016/j.ctrv.2020.102115 PMID: 33130422

4. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149:1060–72. https://doi.org/10.1016/j.cell.2012.03.042 PMID: 22632970

5. Stockwell BR, Jiang X, Gu W. Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020; 30:478–90. https://doi.org/10.1016/j.tcb.2020.02.009 PMID: 32413317

6. Fanzani A, Poli M. Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma. Int J Mol Sci. 2017; 18. https://doi.org/10.3390/ijms18081716 PMID: 28783123

7. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019; 569:270–4. https://doi.org/10.1038/s41586-019-1170-y PMID: 31043744
8. Lu T, Xu R, Li Q, Zhao JY, Peng B, Zhang H, et al. Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma. Mol Ther Oncolytics. 2021; 21:134–43. https://doi.org/10.1016/j.omto.2021.02.011 PMID: 33981829

9. Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020; 2020. https://doi.org/10.1093/database/bbaa021 PMID: 32219413

10. Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014; 58:234–9. https://doi.org/10.1007/s12026-014-8516-1 PMID: 24791905

11. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23:1846–7. https://doi.org/10.1093/bioinformatics/btm254 PMID: 17496320

12. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47. https://doi.org/10.1093/nar/gkv007 PMID: 25605792

13. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016; 32:2847–9. https://doi.org/10.1093/bioinformatics/btw313 PMID: 27207943

14. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012, 16:284–7. https://doi.org/10.1089/omi.2011.0118 PMID: 22454543

15. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43:D447–52. https://doi.org/10.1093/nar/gku1003 PMID: 25352553

16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramme D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13:2498–504. https://doi.org/10.1101/gr.1239303 PMID: 14597658

17. Chun CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. https://doi.org/10.1186/1752-0509-8-S4-S11 PMID: 25521941

18. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniak AD, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173:400–16.e11. https://doi.org/10.1016/j.cell.2018.02.052 PMID: 29625055

19. Iasonos A, Schrag D, Raj GV, Panagases KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26:1364–70. https://doi.org/10.1200/JCO.2007.12.9791 PMID: 18323559

20. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. https://doi.org/10.1186/1471-2105-14-7 PMID: 23328331

21. Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018; 52:39–52. https://doi.org/10.1016/j.semcancer.2017.10.001 PMID: 28987965

22. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019; 18:155. https://doi.org/10.1186/s12943-019-1091-2 PMID: 31690319

23. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39:782–95. https://doi.org/10.1016/j.immuni.2013.10.003 PMID: 24138885

24. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020; 70:200–29. https://doi.org/10.3322/caac.21605 PMID: 32275330

25. Ayodele O, Razak A. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020; 27:17–23. https://doi.org/10.3745/co.27.5407 PMID: 32174754

26. Coley WB. II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891; 14:199–220. https://doi.org/10.1097/00000658-189112000-00015 PMID: 17859590

27. Atherton MJ, Lenz JA, Mason NJ. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy. Vet Comp Oncol. 2020; 18:447–70. https://doi.org/10.1111/vco.12595 PMID: 32246517

28. Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020; 13:110. https://doi.org/10.1186/s13045-020-00946-7 PMID: 32778143

29. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577:556–60. https://doi.org/10.1038/s41586-019-1906-8 PMID: 31942077
30. Klein S, Mauch C, Wagener-Ryczek S, Schoemmel M, Buettner R, Quaas A, et al. Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunol Immunother. 2019; 68:973–82. https://doi.org/10.1007/s00262-019-02339-3 PMID: 30963193

31. Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, et al. PD-1 expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018; 11:16. https://doi.org/10.1186/s13045-018-0560-1 PMID: 31263176

32. Dancsok AR, Setsu N, Gao D, Blay JY, Thomas D, Maki RG, et al. Expression of lymphocyte immuno-regulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol. 2019; 32:1772–85. https://doi.org/10.1038/s41379-019-0312-y PMID: 31263176

33. Nabeshima A, Matsumoto Y, Fukushima J, Iura K, Matsunobu T, Endo M, et al. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-P13K/Akt pathways. Br J Cancer. 2015; 112:547–55. https://doi.org/10.1038/bjc.2014.637 PMID: 25562433

34. Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging Targeted and Immune-Based Therapies in Sarcoma. J Clin Oncol. 2018; 36:125–35. https://doi.org/10.1200/JCO.2017.75.1610 PMID: 29220291

35. Miwa S, Nishida H, Tsuchiya H. Current status of immunotherapy for sarcomas. Immunotherapy. 2017; 9:1331–8. https://doi.org/10.2217/imit-2017-0101 PMID: 29185391

36. Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019; 10:1617. https://doi.org/10.1038/s41467-019-09277-9 PMID: 30962421

37. Nakazawa MS, Eisinger-Mathason TS, Sadri N, Ochocki JD, Gade TP, Amin RK, et al. Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nat Commun. 2016; 7:10539. https://doi.org/10.1038/ncomms10539 PMID: 26837714

38. Zhu T, Wang Z, Wang G, Hu Z, Ding H, Li R, et al. Long non-coding RNA ZFAS1 promotes the expression of EPAS1 in gastric cardia adenocarcinoma. J Adv Res. 2021; 28:7–15. https://doi.org/10.1016/j.jare.2020.06.006 PMID: 33364040

39. Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, et al. EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes. Theranostics. 2017; 7:3293–305. https://doi.org/10.7150/thno.19988 PMID: 28900510

40. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. HEPATOLOGY. 2016; 63:173–84. https://doi.org/10.1002/hep.28251 PMID: 26403645

41. Law CT, Wei L, Tsang FH, Chan CY, Xu IM, Lai RK, et al. HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. HEPATOLOGY. 2019; 69:2013–30. https://doi.org/10.1002/hep.30414 PMID: 30516846

42. Huang W, Duan Y, Yang X, Shang C, Chen X, Zhang H, et al. Identification of Novel Prognostic Risk Signatures of Soft Tissue Sarcoma Based on Ferroptosis-Related Genes. Front Oncol. 2021; 11:629688. https://doi.org/10.3389/fonc.2021.629688 PMID: 33899544

43. Jafarzadeh N, Gholampour MA, Alivand MR, Kavousi S, Arzi L, Rad F, et al. CML derived exosomes promote tumor favorable functional performance in T cells. BMC Cancer. 2021; 21:1002. https://doi.org/10.1186/s12885-021-08734-3 PMID: 34493241

44. Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP, Ghosh R. NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res. 2014; 74:5644–55. https://doi.org/10.1158/0008-5472.CAN-14-0562 PMID: 25125658

45. Zhang X, Du L, Qiao Y, Zhang X, Zheng W, Wu Q, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol. 2019; 24:101211. https://doi.org/10.1016/j.redox.2019.101211 PMID: 31108480

46. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A. 2014; 111:16836–41. https://doi.org/10.1073/pnas.1415518111 PMID: 25383600

47. Zhang R, Gao X, Zuo J, Hu B, Yang J, Zhao J, et al. STN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway. Cancer Sci. 2020; 111:406–17. https://doi.org/10.1111/cas.14262 PMID: 31785057

48. Hu X, Zhang H, Zheng X, Lin Z, Feng G, Chen Y, et al. STN1 and MKI67 Are Upregulated in Uterine Leiomyosarcoma and Are Potential Biomarkers for its Diagnosis. Med Sci Monit. 2020; 26:e923749. https://doi.org/10.12659/MSM.923749 PMID: 32425177
49. Allen MM, Douds JJ, Liang SX, Desouki MM, Parkash V, Fadare O. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Int J Clin Exp Pathol. 2015; 8:2795–801. PMID: 26045786